kabutan

Takeda Pharma, Net Income Forecast for the Fiscal Year Revised Downward by 33%

Thu Oct 30, 2025 3:40 pm JST Earnings

4502 Takeda Pharmaceutical Company Limited 【IFRS】

Earnings Report

Takeda Pharmaceutical Company Limited <4502> [TSE Prime] announced its financial results (based on IFRS) after the market closed on October 30th (15:40). The consolidated net income for the cumulative second quarter of the fiscal year ending March 2026 (April to September) dropped 40.0% from the same period last year to 112 billion yen.

In addition, the full-year forecast for consolidated net income has decreased 32.9%, from the previous forecast of 228 billion yen to 153 billion yen (compared to 107 billion yen in the previous period), leading to a reduction in the profit growth rate from 2.1 times to 41.8%.

Based on the first-half performance announced by the company and the full-year plan, our calculation indicates that the consolidated net income/loss for the October to March period (second half) is expected to turn into a profit of 40.5 billion yen (compared to a loss of 79.3 billion yen in the same period last year).

In the most recent three-month period, from July to September (2Q), the consolidated net income/loss turned to a loss of 11.8 billion yen (compared to a profit of 92.0 billion yen in the same period last year). The operating profit margin sharply declined from 15.7% in the same period last year to 6.2%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Sep, 2023 2,101,707 119,230 39,053 41,365 26.5 74.0 Oct 26, 2023 IFRS
Apr - Sep, 2024 2,384,028 350,576 255,976 187,294 118.9 146.2 Oct 31, 2024 IFRS
Apr - Sep, 2025 2,219,481 253,561 178,804 112,441 71.6 73.6 Oct 30, 2025 IFRS
YoY -6.9% -27.7% -30.1% -40.0% -39.8%

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2025 Guidance ー ー ー ー － 100 May 8, 2025 IFRS
Apr - Sep, 2025 Results 2,219,481 253,561 178,804 112,441 71.6 100 Oct 30, 2025 IFRS
Revision Rate － － － － －

Guidance Update

Full Year Update

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2026 Prev 4,530,000 475,000 307,000 228,000 144.3 200 May 8, 2025 IFRS
Mar, 2026 New 4,500,000 400,000 243,000 153,000 96.9 200 Oct 30, 2025 IFRS
Revision Rate -0.7% -15.8% -20.8% -32.9% -32.9%

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 2,197,523 -7,990 -80,892 -79,366 -50.3 98 May 8, 2025 IFRS
Oct - Mar, 2025 Guidance 2,280,519 146,439 64,196 40,559 25.7 100 Oct 30, 2025 IFRS
YoY +3.8% － － － －

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 4,263,762 214,075 52,791 144,067 92.1 188 May 9, 2024 IFRS
Mar, 2025 4,581,551 342,586 175,084 107,928 68.4 196 May 8, 2025 IFRS
Mar, 2026 Guidance 4,500,000 400,000 243,000 153,000 96.9 200 Oct 30, 2025 IFRS
YoY -1.8% +16.8% +38.8% +41.8% +41.7%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jul - Sep, 2024 1,176,038 184,247 119,372 92,046 58.4 15.7 Oct 31, 2024 IFRS
Oct - Dec, 2024 1,144,124 66,942 26,407 23,789 15.1 5.9 Jan 30, 2025 IFRS
Jan - Mar, 2025 1,053,399 -74,932 -107,299 -103,155 -65.3 -7.1 May 8, 2025 IFRS
Apr - Jun, 2025 1,106,685 184,566 150,630 124,243 79.4 16.7 Jul 30, 2025 IFRS
Jul - Sep, 2025 1,112,796 68,995 28,174 -11,802 -7.5 6.2 Oct 30, 2025 IFRS
YoY -5.4% -62.6% -76.4% － －

Related Articles